BMRN
Price
$61.35
Change
-$0.86 (-1.38%)
Updated
Sep 24 closing price
Capitalization
12.04B
39 days until earnings call
Intraday BUY SELL Signals
IBO
Price
$5.52
Change
-$1.11 (-16.74%)
Updated
Sep 24, 04:56 PM (EDT)
Capitalization
56.89M
Intraday BUY SELL Signals
Interact to see
Advertisement

BMRN vs IBO

BMRN vs IBO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BMRN vs. IBO commentary
Sep 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a StrongBuy and IBO is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BMRN vs IBO: Fundamental Ratings
BMRN
IBO
OUTLOOK RATING
1..100
1597
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
898
PRICE GROWTH RATING
1..100
4750
P/E GROWTH RATING
1..100
223
SEASONALITY SCORE
1..100
5030

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBO's Valuation (74) in the null industry is in the same range as BMRN (97) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.

IBO's Profit vs Risk Rating (100) in the null industry is in the same range as BMRN (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.

IBO's SMR Rating (8) in the null industry is significantly better than the same rating for BMRN (89) in the Biotechnology industry. This means that IBO’s stock grew significantly faster than BMRN’s over the last 12 months.

BMRN's Price Growth Rating (47) in the Biotechnology industry is in the same range as IBO (50) in the null industry. This means that BMRN’s stock grew similarly to IBO’s over the last 12 months.

BMRN's P/E Growth Rating (2) in the Biotechnology industry is in the same range as IBO (23) in the null industry. This means that BMRN’s stock grew similarly to IBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNIBO
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
66%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
18%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
17%
Advances
ODDS (%)
Bullish Trend 8 days ago
60%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
71%
COMPARISON
Comparison
Sep 25, 2026
Stock price -- (BMRN: $62.21 vs. IBO: $6.63)
Brand notoriety: BMRN and IBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 107% vs. IBO: 330%
Market capitalization -- BMRN: $12.04B vs. IBO: $56.89M
BMRN [@Biotechnology] is valued at $12.04B. IBO’s [@Biotechnology] market capitalization is $56.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.87B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 1 FA rating(s) are green while IBO’s FA Score has 2 green FA rating(s).

  • BMRN’s FA Score: 1 green, 4 red.
  • IBO’s FA Score: 2 green, 3 red.
According to our system of comparison, IBO is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 3 TA indicator(s) are bullish while IBO’s TA Score has 5 bullish TA indicator(s).

  • BMRN’s TA Score: 3 bullish, 6 bearish.
  • IBO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IBO is a better buy in the short-term than BMRN.

Price Growth

BMRN (@Biotechnology) experienced а -3.89% price change this week, while IBO (@Biotechnology) price change was +5.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.84%. For the same industry, the average monthly price growth was -10.68%, and the average quarterly price growth was +8.45%.

Reported Earning Dates

BMRN is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BMRN
Daily Signal:
Gain/Loss:
IBO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CARD2.710.08
+3.04%
MAX Auto Industry - 3x Inverse Leveraged ETN (CARD)
IMF53.65N/A
N/A
Invesco Managed Futures Strategy ETF (IMF)
GMOV32.16-0.11
-0.36%
GMO US Value ETF
NTSX59.30-0.90
-1.50%
WisdomTree U.S. Efficient Core Fund (NTSX)
QDTY39.16-0.62
-1.55%
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY)

IBO and

Correlation & Price change

A.I.dvisor tells us that IBO and PCSA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IBO and PCSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBO
1D Price
Change %
IBO100%
-0.43%
PCSA - IBO
32%
Poorly correlated
-1.05%
INDP - IBO
27%
Poorly correlated
-5.51%
LPCN - IBO
27%
Poorly correlated
-1.85%
AZTR - IBO
26%
Poorly correlated
-2.99%
LIMN - IBO
24%
Poorly correlated
-0.98%
More